ARM Innovation Hub
Advertisement: Cambridge Network mid banner
RealVNC mid banner careers
Advertisement: Howard Group mid banner
Advertisement: EY Mid banner
Advertisement: EBCam mid banner
Advertisement: Kao Data Centre mid banner
Advertisement: Hewitsons mid banner
Advertisement – Charles Stanley mid banner
Barr Ellison Solicitors – commercial property
Advertisement: Simpsons Creative
Mid banner advertisement: BDO
Advertisement: RSM
Advertisement mid banner S-Tech 1
Advertisement: Mogrify mid banner
29 November, 2006 - 12:16 By Staff Reporter

York Pharma predicts year of success

Hitchin-based, York Pharma, announced increased pre-tax losses of almost £6m which were in-line with management predictions, but expects a year of commercial success.The period ending September 30 loss was £5.88m compared with £2.69m for the previous year. The firm is confident about the release of its new topical antifungal product, abasol, which is expected to hit the market in early 2007.

It also announced that its new psoriasis drug, Vampex has completed phase IIa clinical trials and eczema treatment Sabarep had entered controlled human trials. The dermatology expert reported a cash pot of £2.9m, generated from the placing of new shares, not included with these results.

Add new comment

Newsletter Subscription

Stay informed of the latest news and features